The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc’s drug to treat spinal muscular atrophy, the leading genetic cause of death in infants. It is the first FDA-approved medicine for spinal muscular atrophy, a devastating disease that affects about one in 10,000 live births. The drug, nusinersen, which was discovered by Ionis Pharmaceuticals and licensed to Biogen, will be sold under the brand name Spinraza.
View original post here:
FDA approves Biogen drug for lead genetic cause of infant death